Signal Peptides & Cell-Penetrating Peptides Explained

Cells have a problem. They need to get the right proteins to the right places --- exporting some outside the cell, embedding others in the membrane, and keeping the rest in the cytoplasm. At the same time, researchers have the opposite problem: they need to get therapeutic molecules into cells that would rather keep them out.

Two categories of short peptide sequences sit at the center of these challenges. Signal peptides are the cell's built-in sorting tags, routing newly made proteins into the secretory pathway. Cell-penetrating peptides (CPPs) are sequences --- some discovered in nature, some designed in labs --- that can cross cell membranes and carry cargo with them. Together, they represent two sides of the same biological coin: how peptides interact with membranes.

Signal Peptides: The Cell's Molecular Zip Codes
How Signal Peptides Work: The Secretory Pathway
Cell-Penetrating Peptides: Breaking Into Cells
Major Classes of Cell-Penetrating Peptides
How CPPs Get Inside: Uptake Mechanisms
Drug Delivery Applications
Current Research and Clinical Progress
Limitations and Challenges
FAQ
The Bottom Line
References

Signal Peptides: The Cell's Molecular Zip Codes

When a cell makes a protein destined for export --- an antibody, a hormone like insulin, a receptor that needs to sit in the membrane --- it attaches a short tag at the beginning of the amino acid chain. This tag is the signal peptide, and it works like a postal code: it tells the cell's internal machinery where the protein should go.

Signal peptides are typically 16 to 30 amino acids long, though some stretch beyond 50. They share no common sequence. You could line up a hundred signal peptides and find almost no matching amino acids. What they share is a common architecture, described as a tripartite structure:

The n-region --- A positively charged stretch at the very beginning, usually containing one to several arginine or lysine residues
The h-region --- A central hydrophobic core of 5 to 15 amino acids that forms an alpha-helix in membrane environments
The c-region --- The cleavage site, where signal peptidase cuts the signal peptide off after the protein crosses the membrane

The cleavage site follows what biochemists call the "-1, -3 rule": small amino acids (alanine, glycine, serine) must occupy specific positions near the cut point. This rule is so consistent that computational tools like SignalP can predict signal peptides from amino acid sequences with over 90% accuracy.

About 30% of all human proteins --- roughly a quarter of the entire proteome --- carry signal peptides that direct them into the endoplasmic reticulum (ER) and the secretory pathway. That makes signal peptides one of the most common functional motifs in biology.

How Signal Peptides Work: The Secretory Pathway

The journey from ribosome to cell surface (or beyond) happens through two main routes.

Co-Translational Targeting (The SRP Pathway)

This is the dominant route in human cells, and it works in real time during protein synthesis:

A ribosome begins translating mRNA, and the signal peptide emerges from the ribosome's exit tunnel
The signal recognition particle (SRP) --- a complex of protein and RNA --- binds the hydrophobic h-region of the signal peptide
SRP pauses translation and escorts the ribosome-mRNA-peptide complex to the ER membrane
At the ER, SRP hands off the complex to the SRP receptor, which docks the ribosome onto the Sec61 translocon --- a protein-conducting channel in the ER membrane
Translation resumes. The growing protein threads through the Sec61 channel into the ER lumen
Signal peptidase clips off the signal peptide. The freed signal peptide is degraded (though some fragments have signaling functions of their own)
The mature protein folds, gets modified (glycosylation, disulfide bonds), and moves through the Golgi to its final destination

The whole system operates with remarkable speed. SRP recognizes a signal peptide within milliseconds of its emergence from the ribosome.

Post-Translational Targeting

Some proteins --- especially short or less hydrophobic ones --- skip the SRP and get targeted to the ER after translation is complete. In these cases, cytoplasmic chaperones (like Hsp70) keep the protein unfolded and translocation-competent until it reaches the membrane. The Sec62/Sec63 complex assists with insertion through the Sec61 channel.

The choice between co-translational and post-translational routes depends largely on the hydrophobicity of the signal peptide. More hydrophobic signals catch SRP's attention; less hydrophobic ones tend to slip through and use the backup pathway.

After Cleavage: Do Signal Peptides Just Disappear?

For decades, the assumption was yes. But research has shown that some cleaved signal peptides stick around and perform secondary functions. Signal peptide fragments from HIV glycoproteins, for instance, interact with immune system molecules (HLA-E) and influence whether natural killer cells attack infected cells. Other signal peptide fragments may act as intracellular signals or regulate the proteins they were originally attached to.

Cell-Penetrating Peptides: Breaking Into Cells

If signal peptides are the cell's internal routing system, cell-penetrating peptides are the lockpicks that let researchers bypass the cell membrane from the outside.

The cell membrane is a lipid bilayer designed to be selectively impermeable. Most therapeutic molecules --- proteins, nucleic acids, many drugs --- cannot cross it on their own. This is one of the biggest obstacles in drug delivery. CPPs offer a potential solution: short peptide sequences (usually under 40 amino acids) that can cross cell membranes without destroying them, often bringing therapeutic cargo along for the ride.

The field started with two accidental discoveries in the late 1980s and early 1990s.

The TAT Story

In 1988, two independent groups (led by Alan Frankel and Howard Green) noticed something odd: the Tat protein from HIV could enter cells from the surrounding medium. This was unexpected --- proteins don't normally cross membranes on their own. By 1994, researchers had narrowed the membrane-crossing ability to an 11-amino-acid stretch from positions 47 to 57: YGRKKRRQRRR. This became the TAT peptide, the founding member of the CPP family.

The Penetratin Story

Around the same time, Alain Prochiantz's group in Paris found that the homeodomain of the Drosophila Antennapedia transcription factor could also enter cells. The active sequence, a 16-amino-acid peptide called penetratin (RQIKIWFQNRRMKWKK), became the second canonical CPP.

Since then, over 100 CPPs have been identified or designed. They are cataloged in databases like CPPsite and studied across thousands of publications.

Major Classes of Cell-Penetrating Peptides

CPPs are grouped by their physical properties and origins.

By Structure

Class	Characteristics	Examples
Cationic CPPs	Rich in positively charged amino acids (arginine, lysine); interact electrostatically with negatively charged membrane components	TAT(47-57), polyarginine (R8, R9), penetratin
Amphipathic CPPs	Contain both hydrophobic and hydrophilic regions; some form alpha-helices that insert into membranes	Transportan, MAP, MPG, Pep-1
Hydrophobic CPPs	Predominantly nonpolar residues; cross membranes through hydrophobic interactions	Integrin beta-3 signal peptide, Pep-7

By Origin

Category	Description	Examples
Protein-derived	Isolated from naturally occurring proteins	TAT (from HIV Tat protein), penetratin (from Drosophila Antennapedia), VP22 (from herpes simplex virus)
Chimeric	Hybrid sequences combining elements from different sources	Transportan (galanin + mastoparan), MPG (HIV gp41 + nuclear localization signal)
Synthetic	Rationally designed or discovered through screening	Polyarginine (R8, R9, R12), MAP (model amphipathic peptide), CADY

The arginine residue deserves special mention. It shows up in CPP after CPP because its guanidinium side chain forms bidentate hydrogen bonds with phosphate and sulfate groups on the cell surface. Oligoarginines as short as R8 (eight arginines in a row) penetrate cells effectively, and this observation has driven enormous interest in arginine-rich delivery vectors.

How CPPs Get Inside: Uptake Mechanisms

Despite three decades of research, exactly how CPPs cross membranes remains debated. The truth is probably that multiple mechanisms operate simultaneously, and the dominant route depends on the CPP, the cargo, the concentration, and the cell type.

Direct Translocation

At higher concentrations, some CPPs (particularly cationic ones) can punch directly through the lipid bilayer without requiring energy. Proposed models include:

Inverted micelle formation --- The CPP creates a small lipid pocket that flips across the membrane
Pore formation --- The CPP creates transient aqueous channels (barrel-stave or toroidal pore models)
Carpet model --- CPPs accumulate on the membrane surface until a critical concentration causes local disruption

Direct translocation is energy-independent (it works at 4 degrees C, when endocytosis is blocked) and typically occurs at higher CPP concentrations.

Endocytosis

At lower, more physiologically relevant concentrations, most CPPs enter through energy-dependent endocytic pathways:

Macropinocytosis --- The cell ruffles its membrane and engulfs surrounding fluid, including CPPs
Clathrin-mediated endocytosis --- CPPs are internalized through clathrin-coated pits
Caveolae-mediated endocytosis --- Uptake through cholesterol-rich membrane invaginations

The catch with endocytic uptake is that CPPs and their cargo often get trapped in endosomes --- membrane-bound compartments inside the cell. Escaping the endosome before its contents are degraded is one of the biggest challenges in CPP-based delivery.

A 2025 study published in Biology of the Cell found that multimeric TAT peptides can permeabilize endosomes without triggering membrane damage responses, challenging the assumption that anything that makes endosomes leaky must be toxic to cells.

Drug Delivery Applications

The real excitement around CPPs lies in their potential as drug delivery vehicles. Here are the major therapeutic areas under investigation.

Cancer Therapy

CPPs are being explored as carriers for chemotherapy drugs, tumor-suppressor proteins, and anticancer nucleic acids. The goal is to get cytotoxic payloads inside cancer cells more efficiently while reducing off-target effects. In 2024, researchers at Shi's group developed cell-penetrating peptide-induced chimeric conjugates (cp-PCCs) that degraded the palmitoyltransferase DHHC3, disrupting PD-L1's immunosuppressive function and boosting anti-tumor immune responses.

Gene Therapy and Nucleic Acid Delivery

CPPs can complex with DNA, siRNA, mRNA, and antisense oligonucleotides to facilitate their entry into cells. This is particularly valuable because nucleic acids are large, negatively charged molecules that have almost no chance of crossing membranes on their own.

Blood-Brain Barrier Penetration

The blood-brain barrier (BBB) blocks over 98% of small-molecule drugs and essentially all large-molecule therapeutics from reaching the brain. CPPs --- particularly TAT, penetratin, and polyarginine --- have shown ability to cross the BBB in animal models. This has generated interest in using CPP-drug conjugates for neurological conditions including Alzheimer's disease, Parkinson's disease, and brain tumors.

Protein and Antibody Delivery

Jiang's group created a cyclized GFP-Tat fusion protein that improved both stability and intracellular delivery efficiency compared to the linear version, with better tumor retention in living animals. Berne's group fused five different CPPs to antibodies, significantly boosting antibody penetration into cells --- a potential breakthrough for targeting intracellular disease proteins.

Vaccine Development

CPPs are being used to deliver antigenic peptide vaccines more effectively to antigen-presenting cells, improving immune responses.

Current Research and Clinical Progress

Where Things Stand

As of 2025, most CPP-based therapeutics are in preclinical or early clinical stages. A few have advanced further:

TAT-linked peptide inhibitors targeting protein-protein interactions in cancer and inflammation have entered Phase I/II trials
CPP-conjugated antimicrobial peptides are being tested against drug-resistant infections
Conditional CPPs --- engineered to activate only in specific environments (low pH in tumors, protease-rich inflamed tissues) --- are addressing the long-standing problem of CPP nonspecificity

A 2025 review in Pharmaceutical Research surveyed design and optimization strategies for CPPs in drug delivery systems, concluding that the field has matured from proof-of-concept demonstrations to systematic engineering of targeted delivery vehicles.

Smart CPP Systems

One of the most active research areas involves making CPPs selective. Classical CPPs like TAT penetrate every cell they encounter, which limits their usefulness as targeted delivery tools. Newer approaches include:

Activatable CPPs --- The CPP is masked by an anionic peptide connected via a cleavable linker. Tumor-associated proteases (like MMPs) cut the linker, exposing the CPP only at the tumor site
pH-sensitive CPPs --- Designed to become membrane-active only in the acidic environment of tumors or endosomes
Receptor-targeted CPP fusions --- The CPP is paired with a targeting ligand (like a tumor-homing peptide or antibody fragment) for cell-type-specific delivery

In 2024, researchers reported in ACS Applied Materials & Interfaces that combining TAT-modified polymer nanoparticles with cell-specific receptor ligands achieved conditional uptake --- the nanoparticles entered only target cells and stayed inert against others.

Limitations and Challenges

For all their promise, CPPs face real obstacles on the road to clinical use.

Endosomal entrapment. Most CPP cargo ends up trapped in endosomes after endocytic uptake. Only a fraction escapes to reach its intracellular target. Improving endosomal escape remains the field's single biggest technical challenge.

Lack of cell specificity. Classical CPPs enter nearly every cell type, creating off-target effects. Conditional and targeted CPP systems address this but add complexity and cost.

Serum instability. Natural L-amino acid CPPs are rapidly degraded by proteases in the bloodstream. Solutions include using D-amino acids (protease-resistant mirror images), cyclizing the peptide, or PEGylating (attaching polyethylene glycol chains) to improve half-life.

Toxicity at high concentrations. At the concentrations needed for direct translocation, some CPPs damage cell membranes. Therapeutic windows must be carefully defined.

Scale and cost. Synthesizing CPP-drug conjugates at pharmaceutical scale adds manufacturing complexity. Solid-phase peptide synthesis is well-established, but conjugation chemistry and quality control for CPP-cargo complexes are still being optimized.

FAQ

What is the difference between a signal peptide and a cell-penetrating peptide?

Signal peptides are natural sequences built into proteins to route them through the cell's own secretory pathway --- they work from inside the cell during protein synthesis. Cell-penetrating peptides work from outside the cell, crossing the membrane to deliver cargo inward. Both interact with lipid membranes, but they serve opposite purposes.

Can signal peptides be used for drug delivery?

In some cases, yes. Researchers have incorporated signal peptide sequences into drug delivery constructs to route therapeutic proteins through the secretory pathway or to target them to specific organelles. But for getting drugs into cells from the outside, CPPs are the primary tool.

Are cell-penetrating peptides safe?

At therapeutic concentrations, CPPs generally have low toxicity. A 2025 review noted that peptide-based delivery systems offer low immunogenicity and a high safety profile compared to viral vectors and lipid nanoparticles. However, toxicity increases at higher concentrations, and long-term safety data from human trials is still limited.

Which CPP is most widely used in research?

TAT(47-57) remains the most studied and cited CPP. Penetratin is a close second. Polyarginine (R8 or R9) is popular for its simplicity. The choice depends on the cargo and application.

Are any CPP-based drugs FDA-approved?

No CPP-based drug has yet received full FDA approval as of early 2026. Several are in clinical trials. The closest precedents are peptide-drug conjugates in oncology, some of which use CPP-like cell-targeting mechanisms. For a list of currently approved peptide medications, see our FDA-approved peptide drug list.

How do CPPs relate to antimicrobial peptides?

There's significant overlap. Many antimicrobial peptides (like LL-37) are cationic and membrane-active --- the same properties that define CPPs. Some AMPs also function as CPPs, and researchers are designing hybrid molecules that combine antimicrobial activity with drug delivery capability.

The Bottom Line

Signal peptides and cell-penetrating peptides demonstrate how short amino acid sequences can control the movement of molecules across biological membranes. Signal peptides do this naturally billions of times per second in every cell in your body, routing about a quarter of all human proteins to their correct destinations. Cell-penetrating peptides exploit similar membrane interactions for therapeutic purposes, offering a way to deliver drugs, genes, and proteins into cells that would otherwise be inaccessible.

The CPP field has matured from the early curiosity-driven discoveries of TAT and penetratin to sophisticated, conditionally activated delivery systems targeting specific diseases. While no CPP-based drug has reached the market yet, the trajectory points toward clinical applications in cancer, neurological disease, and gene therapy within the coming years.

For more on how peptides work at the molecular level or the basics of peptide science, check our reference guides.

References

Signal Peptide Features Determining the Substrate Specificities of Targeting and Translocation Components in Human ER Protein Import. Frontiers in Physiology. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9309488/
Take Me Home, Protein Roads: Structural Insights into Signal Peptide Interactions during ER Translocation. International Journal of Molecular Sciences. 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8584900/
Post-Targeting Functions of Signal Peptides. Madame Curie Bioscience Database. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK6322/
Applications of cell penetrating peptide-based drug delivery system in immunotherapy. Frontiers in Immunology. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11794548/
The Different Cellular Entry Routes for Drug Delivery Using Cell Penetrating Peptides. Biology of the Cell. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12149500/
Recent Advances of Cell-Penetrating Peptides and Their Application as Vectors for Delivery of Peptide and Protein-Based Cargo Molecules. Pharmaceutics. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10459450/
An insight into cell-penetrating peptides: perspectives on design, optimization, and targeting in drug delivery systems. Pharmaceutical Development and Technology. 2025. https://www.tandfonline.com/doi/full/10.1080/10837450.2025.2505000
Cell-Penetrating Peptides --- Mechanisms of Cellular Uptake and Generation of Delivery Systems. Pharmaceuticals. 2014. https://pmc.ncbi.nlm.nih.gov/articles/PMC4034016/
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines. Signal Transduction and Targeted Therapy. 2024. https://www.nature.com/articles/s41392-024-02107-5

Table of Contents